1 – 50 of 76
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Recombinant factor IX Fc for the treatment of hemophilia B
(
- Contribution to journal › Scientific review
-
Mark
Decreased neutrophil function in newly diagnosed multiple myeloma patients is restored with lenalidomide therapy
2024) In European Journal of Haematology(
- Contribution to journal › Article
- 2021
-
Mark
Principles of Care for Acquired Hemophilia
(
- Contribution to journal › Article
- 2019
-
Mark
Inhibitors in haemophilia A and B : Management of bleeds, inhibitor eradication, and strategies for difficult-to-treat patients
(
- Contribution to journal › Scientific review
-
Mark
The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera
(
- Contribution to journal › Article
- 2017
-
Mark
Linear decline of corrected platelet count increment within 24 hours after platelet transfusion in haematological patients : a prospective observational study
(
- Contribution to journal › Article
-
Mark
Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia : A population-based study from the Swedish AML registry
(
- Contribution to journal › Article
- 2016
-
Mark
Season of diagnosis is associated with overall survival in patients with diffuse large B-cell lymphoma but not with Hodgkin's lymphoma - A population-based Swedish Lymphoma Register study.
(
- Contribution to journal › Article
-
Mark
Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
(
- Contribution to journal › Article
-
Mark
Enteric-coated mycophenolate sodium could be an alternative to methotrexate for GVHD prophylaxis.
(
- Contribution to journal › Debate/Note/Editorial
- 2015
-
Mark
Strategies for reducing inhibitor formation in severe haemophilia
(
- Contribution to journal › Scientific review
-
Mark
The ageing patient with haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Various regimens for prophylactic treatment of patients with haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Introduction.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
(
- Contribution to journal › Article
-
Mark
Prevention and treatment of atherosclerosis in haemophilia - how to balance risk of bleeding with risk of ischaemic events
(
- Contribution to journal › Scientific review
-
Mark
One-stage vs. chromogenic assays in haemophilia A
(
- Contribution to journal › Scientific review
-
Mark
Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia.
(
- Contribution to journal › Article
-
Mark
Genetic risk factors for inhibitors in haemophilia A
(
- Contribution to journal › Scientific review
-
Mark
Switching treatments in haemophilia: is there a risk of inhibitor development?
(
- Contribution to journal › Scientific review
-
Mark
Comorbidities and inhibitors in adult patients with haemophilia: issues, costs and management strategies.
(
- Contribution to journal › Scientific review
-
Mark
Interaction between VWF and FVIII in treating VWD
(
- Contribution to journal › Article
-
Mark
Non-genetic risk factors and their influence on the management of patients in the clinic
(
- Contribution to journal › Scientific review
-
Mark
Strategies for inhibitor treatment and costs in the short and long term: a critical evaluation of recent clinical studies
(
- Contribution to journal › Scientific review
-
Mark
Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies.
2015) In European Journal of Haematology(
- Contribution to journal › Article
- 2014
-
Mark
Methods for individualising factor VIII dosing in prophylaxis
(
- Contribution to journal › Scientific review
-
Mark
On-demand treatment in persons with severe haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Perinatal aspects of haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
(
- Contribution to journal › Article
-
Mark
Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B - a systematic literature review
(
- Contribution to journal › Scientific review
-
Mark
High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden
(
- Contribution to journal › Article
-
Mark
Angiogenesis is increased in advanced haemophilic joint disease and characterized by normal pericyte coverage.
(
- Contribution to journal › Article
-
Mark
Outcome measures in haemophilia: a systematic review
(
- Contribution to journal › Scientific review
- 2013
-
Mark
Outcome of poor response paediatric AML using early SCT
(
- Contribution to journal › Article
- 2012
-
Mark
High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy
(
- Contribution to journal › Article
-
Mark
Myeloid malignancies with acquired trisomy 21 as the sole cytogenetic change are clinically highly variable and display a heterogeneous pattern of copy number alterations and mutations(a).
(
- Contribution to journal › Article
-
Mark
Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life.
(
- Contribution to journal › Article
-
Mark
Angptl4 maintains in vivo repopulation capacity of CD34(+) human cord blood cells.
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice.
(
- Contribution to journal › Article
- 2011
-
Mark
Quality of life, physical function and MRI T2*in elderly low-risk MDS patients treated to a haemoglobin level of >= 120 g/L with darbepoetin alfa +/- filgrastim or erythrocyte transfusions
(
- Contribution to journal › Article
-
Mark
Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy
(
- Contribution to journal › Article
-
Mark
When von Willebrand disease comes into age - A matter of change?
(
- Contribution to journal › Article
- 2010
-
Mark
Applicability of IG/TCR gene rearrangements as targets for minimal residual disease assessment in a population-based cohort of Swedish childhood acute lymphoblastic leukaemia diagnosed 2002-2006
(
- Contribution to journal › Article
-
Mark
MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia
(
- Contribution to journal › Article
- 2009
-
Mark
Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas
(
- Contribution to journal › Article
-
Mark
Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study
(
- Contribution to journal › Article
-
Mark
B-cell precursor t(8;14)(q11;q32)-positive acute lymphoblastic leukemia in children is strongly associated with Down syndrome or with a concomitant Philadelphia chromosome.
(
- Contribution to journal › Article
- 2008
-
Mark
U-2973, a novel B-cell line established from a patient with a mature B-cell leukemia displaying concurrent t(14;18) and MYC translocation to a non-IG gene partner.
(
- Contribution to journal › Article
-
Mark
N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
(
- Contribution to journal › Article
- 2007
-
Mark
Serum calcium is an independent predictor of quality of life in multiple myeloma
(
- Contribution to journal › Article